Ledipasvir

ATC Code J05AX16

Ledipasvir

Definition

An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Upon oral administration and after intracellular uptake, ledipasvir binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).

Also known as GS 5885, GS-5885, GS5885, LEDIPASVIR, WHO 9796 — per NCIT

Also identified as

Indications

Disease Relation Source
Chronic hepatitis C virus infection may treat MEDRT · Public domain (U.S. Government work)